Document Detail


TNFalpha in patients with end-stage heart failure on medical therapy or supported by a left ventricular assist device.
MedLine Citation:
PMID:  18346639     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In the heart elevated levels of TNFalpha can cause lethal heart failure, like Dilated Cardiomyopathy (DCM). The level of TNFalpha production is in part determined by promoter gene polymorphisms. We investigated whether the TNFalpha promoter gene polymorphism is in this way involved in the outcome of end-stage heart failure and predicts whether patients require left ventricular assist device (LVAD) support or can be kept on medical therapy (MT)while awaiting heart transplantation (HTx). As most patients in this study received a heart transplant, the role of the TNFalpha polymorphisms in transplant rejection was studied as well. METHODS AND RESULTS: In twenty nine patients with DCM, 35 patients with Ischemic Heart Disease (IHD; both on MT), 26 patients on LVAD support and 61 cardiac transplant donors TNFalpha plasma level was detected by EASIA. In both patients groups high levels of TNFalpha plasma levels was observed however, in patients supported by LVAD this increase was much higher compared to patients on MT. Furthermore, this increase seems to be associated with the TNF 1 allele ('G' at position -308) instead of the TNF2 allele (A at position -308). The promoter polymorphisms at positions -238, -244 and -308 were observed by polymerase chain reaction and sequencing. Polymorphism at positions -238, -244 and -308 did not show any relevant differences between the groups. However, at position -308, a trend of a higher incidence of the TNF2 allele (an "A" at position -308) in DCM patients compared to donors was shown. The distribution of the TNF1 and TNF2 alleles was not different in patients on medical therapy compared to the patients supported by a LVAD. No association was found between patients' TNFalpha promoter gene polymorphism and rejection. However, patients that received a donor heart with the TNF2 allele developed more rejection episodes, compared to patients that received a donor heart with the TNF1 allele. CONCLUSION: TNFalpha levels are high in patients with end-stage heart failure on MT, but even higher in patients on LVAD support. These high TNFalpha plasma levels however, are not correlated with the TNF2 allele but seems to be associated with the TNF1 allele. Furthermore, in HTx the donor TNFalpha gene seem to play a more important role in severity of acute rejection than that of the patient.
Authors:
A H Bruggink; M F M van Oosterhout; N De Jonge; F H J Gmelig-Meyling; R A De Weger
Related Documents :
8933239 - Comparison of the therapeutic effects of the beta-blocking agent bisoprolol and the cal...
1575059 - Mechanical circulatory support with a centrifugal pump after open heart surgery.
19958769 - Chronic heart failure patients with high collagen type i degradation marker levels bene...
2847929 - Evaluation of the safety of enalapril in the treatment of heart failure in the very old.
17383229 - Intestinal paracellular permeability is not affected in chronic congestive heart failure.
2240899 - Serum and tissue magnesium concentrations in patients with heart failure and serious ve...
20013279 - What should we do with a discontinued shunt?
24292799 - Role of vascular endothelial growth factor (vegf) in the neurological manifestations of...
24038489 - In vivo alterations in drug metabolism and transport pathways in patients with chronic ...
Publication Detail:
Type:  Journal Article     Date:  2008-01-28
Journal Detail:
Title:  Transplant immunology     Volume:  19     ISSN:  0966-3274     ISO Abbreviation:  Transpl. Immunol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-18     Completed Date:  2008-08-06     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9309923     Medline TA:  Transpl Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  64-8     Citation Subset:  IM    
Affiliation:
Department of Pathology, University Medical Center Utrecht, P.O. Box 85.500, 3508GA Utrecht, The Netherlands. A.H.Bruggink@lab.azu.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alleles
Genotype
Graft Rejection / genetics*
Heart Failure / genetics,  metabolism*,  therapy
Heart Transplantation*
Heart-Assist Devices*
Humans
Middle Aged
Polymorphism, Genetic
Promoter Regions, Genetic
Tumor Necrosis Factor-alpha / blood*,  genetics
Ventricular Dysfunction, Left / genetics,  metabolism*
Chemical
Reg. No./Substance:
0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The phenotypical and functional characteristics of cord blood monocytes and CD14(-/low)/CD16(+) dend...
Next Document:  Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cell...